dorsaVi Limited (ASX: DVL) has announced two high-credibility commercial agreements generating contracted revenue exceeding A$200,000, marking a material acceleration in the company’s dorsaVi Edge AI Intelligence Expansion across elite sport and European clinical research. Both partnerships validate dorsaVi’s proprietary Onboard Sensor Processing (OSP) technology, which transforms wearable sensors into real-time intelligent systems capable of generating clinical-grade metrics at the point of measurement.
The agreements span a collaboration with Dr. Chirag Patel, ESPN Resident Injury Expert and elite sports physician, and the selection of dorsaVi’s sensors for the SEROMA project, a landmark European clinical study investigating objective outcome measures for Axial Spondyloarthritis (axSpA). Both partners selected dorsaVi following competitive processes, with management highlighting that the credibility conferred by partners of this calibre is expected to accelerate conversations across adjacent markets including pharma, elite sport, occupational health and emerging robotics applications.
dorsaVi announces elite sport and European clinical wins worth over A$200,000
The combined contracted revenue from the Dr. Patel partnership and SEROMA study selection exceeds A$200,000, representing two distinct but strategically connected wins underpinned by a common technology theme: Intelligence at the Ultra Edge. Dr. Patel’s collaboration focuses on developing a premium lower-limb analytics module within the ViMove+ platform for NCAA, elite sport and military applications, whilst the SEROMA project positions dorsaVi as the technology platform for a pivotal European study across six clinical sites investigating sensor-based outcome measures for axSpA.
Both agreements validate dorsaVi’s OSP capability at the highest levels of sport and clinical research. The Select Medical physical therapy network has now surpassed 100 active sites across the United States, with ViMove+ integrated directly onto the Select Hub platform. Trials with additional franchise physiotherapy groups on the US East Coast have commenced and are ongoing, further expanding dorsaVi’s clinical network and validating ViMove+ across diverse practice environments.
The dual nature of these wins opens materially larger addressable markets. The Dr. Patel partnership creates a halo effect expected to accelerate conversations with sporting bodies, military procurement teams and adjacent clinical markets, whilst the SEROMA selection establishes a regulatory track record and European clinical network essential for accessing pharma trials and emerging AI/robotics regulation frameworks.
When big ASX news breaks, our subscribers know first
What is Edge AI and why does it matter for wearable sensors?
Traditional wearable devices capture raw data and transmit it to cloud infrastructure for processing, creating latency that makes real-time intervention impossible in elite sport and remote clinical applications. dorsaVi’s Onboard Sensor Processing (OSP) architecture fundamentally solves this problem through on-device intelligence.
The OSP advantage operates across three critical steps:
- Data capture on device – Sensors collect biomechanical data during movement
- Real-time analysis on device – Algorithms process data directly on the sensor without cloud dependency
- Immediate transmission of refined metrics – Only clinically meaningful insights are transmitted, eliminating latency
This architecture enables validated, clinical-grade metrics at the point of measurement. For Dr. Patel’s elite athletes, this means biomechanical alerts during competition, fatigue markers and injury prevention in real time. For SEROMA’s pharma partners, this means validated spinal mobility metrics at point of assessment, scalable across dispersed trial sites without cloud dependency, and continuous objective metrics for drug efficacy trials.
OSP represents dorsaVi’s core technology differentiator, transforming sensors from passive data collectors into intelligent systems. This creates barriers to entry and justifies premium positioning across sport, clinical and emerging robotics markets, where real-time, validated biomechanical data is increasingly critical.
Dr. Chirag Patel partnership targets elite sport and military markets
dorsaVi has formalised commercial terms with Dr. Chirag Patel for an 8-month project to develop a new premium lower-limb analytics module within the ViMove+ platform. Dr. Patel is Managing Director of New Horizons Foot and Ankle Associates and Founder/CEO of Health AnalySYST, servicing elite athletes across the NFL, NBA, MLB, MLS and USL. His ESPN platform reaches millions of viewers on injury prevention and return-to-play topics.
The project builds directly on successful initial research completed in early 2025, which identified optimal sensor positioning on the lower limb for superior algorithmic outputs. The new phase moves from research to commercial product, capturing real-time biomechanical data on athletes during training and competition. Metrics captured include joint angles, load asymmetry, gait patterns and movement efficiency, with the premium module targeting 2026 revenue.
The halo effect for dorsaVi
A collaboration with a physician of Dr. Patel’s stature at the intersection of elite sport, media and clinical medicine validates dorsaVi’s technology in a highly visible context. This creates a halo effect that management expects to accelerate conversations with other sporting bodies, military procurement teams and adjacent clinical markets. Foot and ankle biomechanics are among the most data-rich and clinically critical domains in human movement, with the sensor data captured in this project representing precisely the structured, high-resolution movement datasets attracting intense interest from humanoid robotics developers seeking to train and validate locomotion models.
Mat Regan, Group CEO of dorsaVi
“Dr. Patel is a clinician with a national media platform and relationships across elite US professional sport… Both selected dorsaVi following competitive processes, which we believe reflects the strength of our technology and platform.”
SEROMA study positions dorsaVi for European pharma market
Axial Spondyloarthritis (axSpA) is a chronic, progressive inflammatory condition causing pain, stiffness and loss of spinal function. Despite affecting millions globally, the condition has lacked a reliable, objective clinical measure of disease progression. The current standard, the BASMI index, has recently been downgraded in the ASAS-OMERACT Core Outcome Set due to poor reliability and limited sensitivity. SEROMA is designed to replace it with a validated, sensor-based alternative.
dorsaVi’s sensors and ViMove+ software have been selected following a competitive review as the technology platform for the SEROMA project, a landmark European clinical study investigating objective outcome measures for axSpA across six European sites. The SEROMA consortium brings together leading European rheumatologists, with direct involvement of the Assessment of Spondyloarthritis International Society (ASAS), representing over 200 axSpA researchers globally. Three global pharmaceutical companies are already engaged, recognising that validated, sensor-based outcome measures are urgently needed for drug approval trials under FDA and EMA frameworks.
Following competitive selection, dorsaVi was chosen for its proven expertise in clinical sensor technology, strong IP, affordable and collaborative business model, and track record of innovation enabling expansion into whole-spine assessment protocols. The selection by a leading European clinical consortium is well-timed, with Europe establishing new regulatory frameworks governing AI and autonomous systems in healthcare and robotics that place a premium on validated, clinically-anchored sensor technology.
Commercial pathway from validation to recurring revenue
Once validated, the SEROMA sensor-based outcome measure is expected to be rapidly adopted in global pharmaceutical trials, creating recurring revenue through licensing, service agreements and platform subscriptions. Beyond pharma, the validated methodology extends across rheumatology and other musculoskeletal conditions, multiplying the addressable market.
| Phase | Milestone | Commercial Outcome |
|---|---|---|
| 1 | Regulatory endorsement via ASAS | Broad clinical adoption; replaces BASMI as gold standard |
| 2 | Pharma integration into pivotal axSpA drug trials | Recurring licensing and service revenue |
| 3 | Extension across rheumatology and MSK diseases | Multiplied addressable market; academic and clinical uptake |
Select Network momentum and US expansion underway
The Select Medical physical therapy network has now surpassed 100 active sites across the United States, with targeted expansion into additional states currently underway. ViMove+ has been integrated directly onto the Select Hub platform, streamlining deployment and deepening the clinical workflow integration that has driven adoption to date.
Trials with additional franchise physiotherapy groups on the US East Coast have commenced and are ongoing. Early engagement data is reinforcing the platform’s clinical utility and the willingness of physio practices to adopt objective, sensor-based movement assessment as part of routine care. Management sees the East Coast trial activity as a meaningful pipeline development channel, with structured conversion pathways into the Select model.
Key momentum indicators include:
- 100+ active sites across the Select Medical network
- ViMove+ integrated onto Select Hub platform for scalable deployment
- Trials commenced with additional franchise groups on US East Coast
- Geographic expansion into new US states underway
Robotics data opportunity and semiconductor roadmap
Beyond the clinical and sporting markets, dorsaVi’s leadership has identified a longer-horizon opportunity: the role of high-quality human movement data in the development of humanoid robotics. The global robotics market is projected to reach US$372.59 billion by 2034, with a critical bottleneck being the availability of validated, high-resolution biomechanical data, particularly for complex movements such as foot and ankle articulation, spinal flexion and multi-joint coordination under load.
dorsaVi’s clinical-grade sensor data, validated against the gold-standard Vicon system to within 1-2 degrees, represents precisely the structured movement dataset that robotics developers require to train, test and refine locomotion models. The foot and ankle metrics being developed with Dr. Patel, and the spinal mobility data captured in SEROMA, represent sensor data categories of direct relevance to next-generation robotic systems.
dorsaVi’s investment in neuromorphic computing and Resistive RAM (RRAM), advanced through collaboration with ITRI (Taiwan) and NTU (Singapore), targets the 22-nm technology node with compute-in-memory efficiency exceeding 20 TOPS/W. This capability will materially extend what dorsaVi’s sensors can detect and report in real time, with both Dr. Patel’s elite sport clients and the SEROMA pharma partners being prospective beneficiaries of the step-change in OSP performance these technologies will enable.
Technology investment highlights include:
- 22-nm RRAM/neuromorphic program targeting ultra-low power, high-speed on-device AI inference
- Collaboration partners: ITRI (Taiwan) and NTU (Singapore)
- Target compute efficiency: >20 TOPS/W (Tera Operations Per Second per Watt)
The next major ASX story will hit our subscribers first
Investment snapshot
The announcements represent a meaningful acceleration in dorsaVi’s commercial trajectory and technology leadership, with both partnerships validating dorsaVi’s “Intelligence at the Ultra Edge” strategy at the highest levels of sport and clinical research. The credibility conferred by partners of this calibre is expected to accelerate conversations across adjacent markets, whilst the same data quality attracting Dr. Patel and pharma partners has emerging value for robotics developers requiring validated movement datasets.
| Theme | Detail |
|---|---|
| Revenue | >A$200,000 contracted from two new agreements |
| Network Scale | 100+ Select sites; US expansion underway |
| Clinical Credibility | ESPN injury expert + European pharma consortium |
| Technology Edge | OSP delivers real-time on-device AI inference |
| Adjacent Markets | Foot/ankle and spinal data relevant to robotics |
Get Healthcare News Before the Market Moves
Join 20,000+ investors receiving FREE breaking ASX healthcare announcements delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving real-time alerts the moment market-moving news breaks across biotech, medtech and digital health sectors.